CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Aera Therapeutics
Company Type: Therapeutics
Main focus: Protein nanoparticles (PNP)
Company stage: Pre-clinical
Diseases: Multiple malignancies, including solid tumours
Genome-editing tool: Licensed therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes
Funding stage: Series B
Location: Cambridge, Massachusetts, USA
Website: https://aeratx.com
Pipeline: Not disclosed
Partners:
Aera Therapeutics is an R&D company leveraging its proprietary protein nanoparticle (PNP) delivery platform. PNPs are derived from retroelements that self-assemble to form capsid-like structures, which can package and transfer nucleic acid cargo. This platform can deliver a variety of cargos including siRNAs and CRISPR/Cas-based platforms regardless of the payload size, and thus holds potential for the development of potent genetic therapeutics.
